Cited by 915Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 216 of the 218 references it cites were found in a registry or an index.

American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

Open access

Azzoli, Christopher G., Baker, Sherman, Temin, Sarah, Pao, William, Aliff, Timothy, Brahmer, Julie, Johnson, David H., Laskin, Janessa L., Masters, Gregory, Milton, Daniel, Nordquist, Luke, Pfister, David G., Piantadosi, Steven, Schiller, Joan H., Smith, Reily, Smith, Thomas J., Strawn, John R., Trent, David, Giaccone, Giuseppe·2009·Journal of Clinical Oncology

DOI 10.1200/jco.2009.23.5622PMC PMC2793036

Open this paper in CoChat — free account

Abstract

The purpose of this article is to provide updated recommendations for the treatment of patients with stage IV non-small-cell lung cancer. A literature search identified relevant randomized trials published since 2002. The scope of the guideline was narrowed to chemotherapy and biologic therapy. An Update Committee reviewed the literature and made updated recommendations. One hundred sixty-two publications met the inclusion criteria. Recommendations were based on treatment strategies that improve overall survival. Treatments that improve only progression-free survival prompted scrutiny of toxicity and quality of life. For first-line therapy in patients with performance status of 0 or 1, a platinum-based two-drug combination of cytotoxic drugs is recommended. Nonplatinum cytotoxic doublets are acceptable for patients with contraindications to platinum therapy. For patients with performance status of 2, a single cytotoxic drug is sufficient. Stop first-line cytotoxic chemotherapy at disease progression or after four cycles in patients who are not responding to treatment. Stop two-drug cytotoxic chemotherapy at six cycles even in patients who are responding to therapy. The first-line use of gefitinib may be recommended for patients with known epidermal growth factor receptor (EGFR) mutation; for negative or unknown EGFR mutation status, cytotoxic chemotherapy is preferred. Bevacizumab is recommended with carboplatin-paclitaxel, except for patients with certain clinical characteristics. Cetuximab is recommended with cisplatin-vinorelbine for patients with EGFR-positive tumors by immunohistochemistry. Docetaxel, erlotinib, gefitinib, or pemetrexed is recommended as second-line therapy. Erlotinib is recommended as third-line therapy for patients who have not received prior erlotinib or gefitinib. Data are insufficient to recommend the routine third-line use of cytotoxic drugs. Data are insufficient to recommend routine use of molecular markers to select chemotherapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2009.23.5622

Cites

216 of 216 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Self-citation
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citation
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours
Goldstraw, P., Crowley, J., Chansky, K., Giroux, D. J., Groome, P. A., Rami-Porta, R., Postmus, P. E., Rusch, V., & Sobin, L. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31812f3c1a · Cited by 3,655

Show all 218 references

Research works printed but not linked: 7

10.1200/jco.2002.20.5.1335 · DOI
Lynch TJ, Presented at the 12th World Conference on Lung Cancer
Lord RV, 2002, Clin Cancer Res, 8, 2286
Mihaylova Z, 2007, J BUON, 12, 105
Langer CJ, 2004, Oncology, 18, 17
Brose MS, 2002, Cancer Res, 62, 6997
Suzuki Y, 1990, Oncogene, 5, 1037

Sorted by citations

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
Travis, W. D., Brambilla, E. M., Noguchi, M., Nicholson, A. G., Geisinger, K. R., Yatabe, Y., Beer, D. G., Powell, C. A., Riely, G. J., Schil, P. E. V., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318206a221 · Cited by 4,834
Self-citation
Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC
Ramalingam, S. S., Vansteenkiste, J., Planchard, D., Cho, B. C., Gray, J. E., Ohe, Y., Zhou, C., Reungwetwattana, T., Cheng, Y., Chewaskulyong, B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913662 · Cited by 2,914
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Wu, Y.-L., Zhou, C., Hu, C.-P., Feng, J., Lu, S., Huang, Y., Li, W., Hou, M., Shi, J. H., Lee, K. Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70604-1 · Cited by 1,978
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A. E., ELIAS, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,612
A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)
Shi, Y., Au, J. S. K., Thongprasert, S., Srinivasan, S., Tsai, C., Khoa, M. T., Heeroma, K., Itoh, Y., Cornelio, G. H., & Yang, P. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000033 · Cited by 1,575
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Dacic, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J.-S., Squire, J., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318290868f · Cited by 1,280
Self-citation
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
Cappuzzo, F., Ciuleanu, T., Stelmakh, L., Cicenas, S., Szczésna, A., Juhász, E., Esteban, E., Molinier, O., Brugger, W., Melezínek, I., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70112-1 · Cited by 1,186
Self-citation
Non-small-cell lung cancer
Gridelli, C., Rossi, A., Carbone, D. P., Guarize, J., Karachaliou, N., Mok, T. S. K., Petrella, F., Spaggiari, L., & Rosell, R. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.9 · Cited by 1,162
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
Barlési, F., Mazières, J., Merlio, J., Debieuvre, D., Mosser, J., Léna, H., Ouafik, L., Besse, B., Rouquette, I., Westeel, V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00004-0 · Cited by 1,000
Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
Masters, G. A., Temin, S., Azzoli, C. G., Giaccone, G., Baker, S., Brahmer, J. R., Ellis, P. M., Gajra, A., Rackear, N., Schiller, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1342 · Cited by 850
Self-citation
The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis
Zhang, Y., Yuan, J.-Q., Wang, K., Fu, X., Han, X., Threapleton, D. E., Yang, Z., Mao, C., & Tang, J.-L. (2016) · Oncotarget · doi:10.18632/oncotarget.12587 · Cited by 866
Cisplatin Induces a Mitochondrial-ROS Response That Contributes to Cytotoxicity Depending on Mitochondrial Redox Status and Bioenergetic Functions
Marullo, R., Werner, E., Degtyareva, N., Moore, B., Altavilla, G., Ramalingam, S. S., & Doetsch, P. W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081162 · Cited by 777
Non–Small Cell Lung Cancer
_, _. (2008) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2008.0021 · Cited by 737
Non-small-cell lung cancer
Goldstraw, P. G., Ball, D., Jett, J. R., Chevalier, T. L., Lim, E. K. S., Nicholson, A. G., & Shepherd, F. A. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62101-0 · Cited by 741
American Society of Clinical Oncology Identifies Five Key Opportunities to Improve Care and Reduce Costs: The Top Five List for Oncology
Schnipper, L. E., Smith, T. J., Raghavan, D., Blayney, D. W., Ganz, P. A., Mulvey, T. M., & Wollins, D. S. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8375 · Cited by 650
Self-citation
Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
Rugo, H. S., Rumble, R. B., Macrae, E. R., Barton, D. L., Connolly, H. K., Dickler, M. N., Fallowfield, L. J., Fowble, B. F., Ingle, J. N., Jahanzeb, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1487 · Cited by 640
PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer
Paz-Ares, L. G., de Marinis, F., Dediu, M., Thomas, M., Pujol, J.-L., Bidoli, P., Molinier, O., Sahoo, T. P., Laack, E., Reck, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.1102 · Cited by 624
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial
Paz-Ares, L., de Marinis, F., Dediu, M., Thomas, M., Pujol, J.-L., Bidoli, P., Molinier, O., Sahoo, T. P., Laack, E., Reck, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70063-3 · Cited by 610
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial
Quoix, E., Zalcman, G., Oster, J.-P., Westeel, V., Pichon, E., Lavolé, A., Dauba, J., Debieuvre, D., Souquet, P.-J., Bigay-Game, L., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60780-0 · Cited by 566
Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)
Inoue, A., Kobayashi, K., Maemondo, M., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mds214 · Cited by 540
American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy
Keedy, V. L., Temin, S., Somerfield, M. R., Beasley, M. B., Johnson, D. H., McShane, L. M., Milton, D. T., Strawn, J. R., Wakelee, H. A., & Giaccone, G. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8923 · Cited by 490
Self-citation
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors
Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Đačić, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J., Squire, J. A., et al. (2013) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.03.001 · Cited by 461
Self-citation
Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update
Hanna, N. H., Schneider, B. J., Temin, S., Baker, S., Brahmer, J. R., Ellis, P. M., Gaspar, L. E., Haddad, R. Y., Hesketh, P. J., Jain, D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03022 · Cited by 467
Self-citation
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Đačić, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J., Squire, J. A., et al. (2013) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0720-oa · Cited by 426
Self-citation
Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non–Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study
Corre, R., Greillier, L., Le Caër, H., Audigier-Valette, C., Baize, N., Bérard, H., Falchero, L., Monnet, I., Dansin, E., Vergnenègre, A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.5839 · Cited by 403
Classification and Pathology of Lung Cancer
Zheng, M. (2016) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2016.02.003 · Cited by 431
Bending the Cost Curve in Cancer Care
Smith, T. J., & Hillner, B. E. (2011) · New England Journal of Medicine · doi:10.1056/nejmsb1013826 · Cited by 397
Self-citation
Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial
Wang, J., Lu, S., Yu, X., Hu, Y., Sun, Y., Wang, Z., Zhao, J., Yu, Y., Hu, C., Yang, K., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.0366 · Cited by 396
Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer
Fennell, D. A., Summers, Y., Cadranel, J. L., Benepal, T., Christoph, D. C., Lal, R., Das, M., Maxwell, F., Visseren‐Grul, C., & Ferry, D. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.01.003 · Cited by 382
PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer
Patel, J. D., Socinski, M. A., Garon, E. B., Reynolds, C. H., Spigel, D. R., Olsen, M. R., Hermann, R. C., Jotte, R. M., Beck, T., Richards, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.9626 · Cited by 369
Odyssey of a cancer nanoparticle: From injection site to site of action
Nichols, J. W., & Bae, Y. H. (2012) · Nano Today · doi:10.1016/j.nantod.2012.10.010 · Cited by 369
Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Giordano, S. H., Temin, S., Kirshner, J. J., Chandarlapaty, S., Crews, J. R., Davidson, N. E., Esteva, F. J., Gonzalez-Angulo, A. M., Krop, I. E., Levinson, J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.0948 · Cited by 352
Self-citation
Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies
Ho, G., Woodward, N. E., & Coward, J. I. G. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.03.014 · Cited by 326
Subclassification of Non-small Cell Lung Carcinomas Lacking Morphologic Differentiation on Biopsy Specimens
Mukhopadhyay, S., & Katzenstein, A.-L. A. (2010) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3182036d05 · Cited by 313
EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples
Ellison, G., Zhu, G., Moulis, A., Dearden, S., Speake, G., & McCormack, R. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2012-201194 · Cited by 301
Comorbidity in older adults with cancer
Williams, G. R., MacKenzie, A. R., Magnuson, A. M., Olin, R. L., Chapman, A. E., Mohile, S. G., Allore, H. G., Somerfield, M. R., Targia, V., Extermann, M., et al. (2015) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2015.12.002 · Cited by 298
Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer
Feng, K., Guo, Y., Dai, H., Wang, Y., Li, X., Jia, H., & Han, W. (2016) · Science China Life Sciences · doi:10.1007/s11427-016-5023-8 · Cited by 297
2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
Azzoli, C. G., Temin, S., Aliff, T. B., Baker, S., Brahmer, J. R., Johnson, D. H., Laskin, J. L., Masters, G. A., Milton, D. T., Nordquist, L. T., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.2774 · Cited by 290
Self-citation
Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop
Pirker, R., Herth, F. J. F., Kerr, K. M., Filipits, M., Tarón, M., Gandara, D. R., Hirsch, F. R., Grunenwald, D. H., Popper, H., Smit, E. F., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f1c8de · Cited by 283
Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial
Quoix, É., Ramlau, R., Westeel, V., Pápai, Z., Madroszyk, A., Riviere, A., Koralewski, P., Breton, J.-L., Stoelben, E., Braun, D., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70259-5 · Cited by 269
Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations
Lin, A., Wei, T., Meng, H., Luo, P., & Zhang, J. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1062-7 · Cited by 266
DNA Damage Triggers Golgi Dispersal via DNA-PK and GOLPH3
Farber-Katz, S., Dippold, H. C., Buschman, M. D., Peterman, M. C., Xing, M., Noakes, C., Tat, J., Ng, M. M., Rahajeng, J., Cowan, D. M., et al. (2014) · Cell · doi:10.1016/j.cell.2013.12.023 · Cited by 261
NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology
Febbo, P. G., Ladanyi, M., Aldape, K., Marzo, A. M. D., Hammond, M. E. H., Hayes, D. F., Iafrate, A. J., Kelley, R. K., Marcucci, G., Ogino, S., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0137 · Cited by 262
Self-citation
The Role of Inflammation in Lung Cancer
Gomes, M. P., Teixeira, A. L., Coelho, A., Araújo, A., & Medeiros, R. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-0348-0837-8_1 · Cited by 257
Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non–Small-Cell Lung Cancer
Paz-Ares, L. G., Biesma, B., Heigener, D. F., von Pawel, J., Eisen, T., Bennouna, J., Zhang, L., Liao, M., Sun, Y., Gans, S. J. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.7646 · Cited by 248
Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles
Rossi, A., & Maïo, M. D. (2016) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1170596 · Cited by 246
Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2–Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Partridge, A. H., Rumble, R. B., Carey, L., Come, S. E., Davidson, N. E., Leo, A. D., Gralow, J. R., Hortobágyi, G. N., Moy, B., Yee, D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.7479 · Cited by 239
Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non–Small-Cell Lung Cancer
Pérol, M., CHOUAID, C., Pérol, D., Barlési, F., Gervais, R., Westeel, V., Créquit, J., Léna, H., Vergnenégre, A., Zalcman, G., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.9782 · Cited by 231
Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial
Zhang, L., Ma, S., Song, X., Han, B., Cheng, Y., Huang, C., Yang, S., Liu, X., Liu, Y., Lü, S., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70117-1 · Cited by 228
Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer
Schvartsman, G., Peng, S. A., Bis, G., Lee, J. J., Benveniste, M. F. K., Zhang, J. J., Roarty, E. B., Lacerda, L., Swisher, S. G., Heymach, J. V., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.07.034 · Cited by 217
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial
Quoix, É., Léna, H., Losonczy, G., Forget, F., CHOUAID, C., Pápai, Z., Gervais, R., Ottensmeier, C. H. H., Szczęsna, A., Każarnowicz, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00483-0 · Cited by 219
Cisplatin Selects for Multidrug-Resistant CD133+ Cells in Lung Adenocarcinoma by Activating Notch Signaling
Liu, Y., Yang, C., Huang, M.-S., Yeh, C., Wu, A. T. H., Lee, Y., Lai, T., Lee, C.-H., Hsiao, Y.-W., Lu, J., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1733 · Cited by 210
Basic Mechanisms of Therapeutic Resistance to Radiation and Chemotherapy in Lung Cancer
Willers, H., Azzoli, C. G., Santivasi, W. L., & Xia, F. (2013) · The Cancer Journal · doi:10.1097/ppo.0b013e318292e4e3 · Cited by 214
Self-citation
Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways
León, G., MacDonagh, L., Finn, S. P., Cuffe, S. D., & Barr, M. P. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.12.001 · Cited by 201
Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: American Society of Clinical Oncology Clinical Practice Guideline
Ramakrishna, N. R., Temin, S., Chandarlapaty, S., Crews, J. R., Davidson, N. E., Esteva, F. J., Giordano, S. H., Gonzalez-Angulo, A. M., Kirshner, J. J., Krop, I. E., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.0955 · Cited by 191
Self-citation
Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS
Korpanty, G. J., Graham, D. M., Vincent, M. D., & Leighl, N. B. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00204 · Cited by 179
Age is a prognostic factor affecting survival in lung cancer patients
Taş, F., Çiftçi, R., Kılıç, L., & Karabulut, S. (2013) · Oncology Letters · doi:10.3892/ol.2013.1566 · Cited by 169
Phase III Trial Comparing Oral S-1 Plus Carboplatin With Paclitaxel Plus Carboplatin in Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer: Results of a West Japan Oncology Group Study
Okamoto, I., Yoshioka, H., Morita, S., Ando, M., Takeda, K., Seto, T., Yamamoto, N., Saka, H., Asami, K., Hirashima, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.0326 · Cited by 165
Personalized medicine in lung cancer: what we need to know
Mok, T. S. K. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.126 · Cited by 165
Treatment of advanced non small cell lung cancer.
Bareschino, M. A., Schettino, C., Rossi, A., Maione, P., Sacco, P. C., Zeppa, R., & Gridelli, C. (2011) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2010.12.08 · Cited by 161
First-Line Gefitinib in Patients Aged 75 or Older With Advanced Non–Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: NEJ 003 Study
Maemondo, M., Minegishi, Y., Inoue, A., Kobayashi, K., Harada, M., Okinaga, S., Morikawa, N., Oizumi, S., Tanaka, T., Isobe, H., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318260de8b · Cited by 155
Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset
Ohe, Y., Imamura, F., Nogami, N., Okamoto, I., Kurata, T., Kato, T., Sugawara, S., Ramalingam, S. S., Uchida, H., Hodge, R. A., et al. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyy179 · Cited by 156
A critical review of recent developments in radiotherapy for non-small cell lung cancer
Baker, S. E., Dahele, M. R., Lagerwaard, F. J., & Senan, S. (2016) · Radiation Oncology · doi:10.1186/s13014-016-0693-8 · Cited by 149
Self-citation
The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies
Liu, X., Lu, Y., Zhu, G., Yao, L., Li, Z., Qin, H., Tang, C., Ellison, G., McCormack, R., & Ji, Q. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2013-201728 · Cited by 146
Lung Cancer Biomarkers: Present Status and Future Developments
Cagle, P. T., Allen, T. C., & Olsen, R. J. (2013) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2013-0319-cr · Cited by 146
Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer
Hirsh, V., Paz-Ares, L. G., Boyer, M. J., Rosell, R., Middleton, G., Eberhardt, W., Szczęsna, A., Reiterer, P., Saleh, M. N., Arrieta, O. G., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.8971 · Cited by 141
Self-citation
Treatment of Lung Cancer
Gadgeel, S. M., Ramalingam, S. S., & Kalemkerian, G. P. (2012) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2012.06.003 · Cited by 144
Managing Treatment-Related Adverse Events Associated with egfr Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer
Hirsh, V. (2011) · Current Oncology · doi:10.3747/co.v18i3.877 · Cited by 138
Prognosis in advanced lung cancer – A prospective study examining key clinicopathological factors
Simmons, C. P. L., Koinis, F., Fallon, M., Fearon, K. C. H., Bowden, J., Solheim, T. S., Grønberg, B. H., McMillan, D. C., Gioulbasanis, I., & Laird, B. J. A. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.03.020 · Cited by 130
The Evolution of Therapies in Non-Small Cell Lung Cancer
Boolell, V., Alamgeer, M., Watkins, D. N., & Ganju, V. (2015) · Cancers · doi:10.3390/cancers7030864 · Cited by 130
Prevalence of Off-Label Use and Spending in 2010 Among Patent-Protected Chemotherapies in a Population-Based Cohort of Medical Oncologists
Conti, R. M., Bernstein, A., Villaflor, V. M., Schilsky, R. L., Rosenthal, M. B., & Bach, P. B. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7252 · Cited by 127
EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation
Antonicelli, A., Cafarotti, S., Indini, A., Galli, A., Russo, A., Cesario, A., Lococo, F., Russo, P., Mainini, A. F., Bonifati, L. G., et al. (2013) · International Journal of Medical Sciences · doi:10.7150/ijms.4609 · Cited by 131
Oncogenic Pathways, Molecularly Targeted Therapies, and Highlighted Clinical Trials in Non–Small-Cell Lung Cancer (NSCLC)
Reungwetwattana, T., Weroha, S. J., & Molina, J. R. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.09.004 · Cited by 127
Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer Treated with Erlotinib
Mileshkin, L., Hicks, R. J., Hughes, B. G. M., Mitchell, P. L. R., Charu, V., Gitlitz, B. J., MACFARLANE, D. J., Solomon, B., Amler, L. C., Yu, W. H., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2763 · Cited by 124
Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer
Castria, T. B. D., da Silva, E. M., de Góis, A. F. T., & Riera, R. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009256.pub2 · Cited by 122
Curcumin and lung cancer—a review
Mehta, H. J., Patel, V. J., & Sadikot, R. T. (2014) · Targeted Oncology · doi:10.1007/s11523-014-0321-1 · Cited by 121
Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer
Connolly, G. C., Dalal, M. R., Lin, J., & Khorana, A. A. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.09.007 · Cited by 118
The Efficacy of Chinese Herbal Medicine as an Adjunctive Therapy for Advanced Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis
Li, S. G., Chen, H., Ou-Yang, C. S., Wang, X., Yang, Z., Tong, Y., & Cho, W. C. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057604 · Cited by 117
First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study
Gatzemeier, U., von Pawel, J., Vynnychenko, I. O., Zatloukal, P., de Marinis, F., Eberhardt, W., Paz-Ares, L. G., Schumacher, K.-M., Goddemeier, T., O'Byrne, K. J., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70278-3 · Cited by 116
Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: The association with treatment efficacy of pemetrexed
Chen, C., Chang, Y., Shih, J., Lin, J., Chen, K., Yang, C.-H., Yu, C., & Yang, P. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.01.024 · Cited by 113
Nomogram to predict the presence ofEGFRactivating mutation in lung adenocarcinoma
Girard, N., Sima, C. S., Jackman, D. M., Sequist, L. V. D., Chen, H., Yang, J. C., Ji, H., Waltman, B. A., Rosell, R., Tarón, M., et al. (2011) · European Respiratory Journal · doi:10.1183/09031936.00010111 · Cited by 113
Self-citation
Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme
Grossi, F., Crinò, L., Logroscino, A., Canova, S., Delmonte, A., Melotti, B., Proto, C., Gelibter, A., Cappuzzo, F., Turci, D., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.05.015 · Cited by 111
Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis
Bria, E., Milella, M., Cuppone, F., Novello, S., Ceribelli, A., Vaccaro, V., Sperduti, I., Gelibter, A. J., Scagliotti, G. V., Cognetti, F., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq742 · Cited by 110
Randomized Phase III Trial Comparing Weekly Docetaxel Plus Cisplatin Versus Docetaxel Monotherapy Every 3 Weeks in Elderly Patients With Advanced Non–Small-Cell Lung Cancer: The Intergroup Trial JCOG0803/WJOG4307L
Abe, T., Takeda, K., Ohe, Y., Kudoh, S., Ichinose, Y., Okamoto, H., Yamamoto, N., Yoshioka, H., Minato, K., Sawa, T., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.8627 · Cited by 110
Biologically Targeted Cancer Therapy and Marginal Benefits: Are We Making Too Much of Too Little or Are We Achieving Too Little by Giving Too Much?
Fojo, T., & Parkinson, D. R. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1277 · Cited by 110
Comparison of liquid-based to tissue-based biopsy analysis by targeted next generation sequencing in advanced non-small cell lung cancer: a comprehensive systematic review
Esagian, S. M., Grigoriadou, G., Nikas, I. P., Boikou, V., Sadow, P. M., Won, J., & Economopoulos, K. P. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03267-x · Cited by 115
Rare cancers: a sea of opportunity
Boyd, N., Dancey, J. E., Gilks, C. B., & Huntsman, D. D. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00386-1 · Cited by 107
Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data
Rossi, A., Chiodini, P., Sun, J., O'Brien, M. E. R., von Plessen, C., Barata, F. J., Park, K., Popat, S., Bergman, B., Parente, B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70402-4 · Cited by 110
Use of molecular markers for predicting therapy response in cancer patients
Duffy, M. J., O’Donovan, N., & Crown, J. P. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.07.004 · Cited by 107
Outcomes of airway stenting for advanced lung cancer with central airway obstruction
Saji, H., Furukawa, K., Tsutsui, H., Tsuboi, M., Ichinose, S., Usuda, J., Ohira, T., & Ikeda, N. (2010) · Interactive Cardiovascular and Thoracic Surgery · doi:10.1510/icvts.2010.238196 · Cited by 105
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Beyond Progressive Disease: A Retrospective Analysis for Japanese Patients with Activating EGFR Mutations
Nishie, K., Kawaguchi, T., Tamiya, A., Mimori, T., Takeuchi, N., Matsuda, Y., Omachi, N., Asami, K., Okishio, K., Atagi, S., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31826913f7 · Cited by 104
Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy
Coudert, B. P., Ciuleanu, T., Park, K., Wu, Y.-L. L. C., Giaccone, G., Brugger, W., Gopalakrishna, P., & Cappuzzo, F. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr125 · Cited by 104
Self-citation
Conquering lung cancer: current status and prospects for the future
Pirker, R. (2020) · Pulmonology · doi:10.1016/j.pulmoe.2020.02.005 · Cited by 101
Management of Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: ASCO Guideline Update
Ramakrishna, N. R., Anders, C. K., Lin, N., Morikawa, A., Temin, S., Chandarlapaty, S., Crews, J. R., Davidson, N. E., Franzoi, M. A., Kirshner, J. J., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00520 · Cited by 109
Self-citation
Targeting BET bromodomain proteins in solid tumors
Sahai, V., Redig, A. J., Collier, K. A., Eckerdt, F., & Munshi, H. G. (2016) · Oncotarget · doi:10.18632/oncotarget.9804 · Cited by 103
Genotype-driven therapies for non-small cell lung cancer: focus on EGFR , KRAS and ALK gene abnormalities
Gaughan, E. M., & Costa, D. B. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834010397569 · Cited by 104
Crizotinib in the treatment of non-small-cell lung cancer
Forde, P. M., & Rudin, C. M. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.688029 · Cited by 100
Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary
Hanna, N. H., Johnson, D. H., Temin, S., & Masters, G. A. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2017.026716 · Cited by 105
Self-citation
A Reversible Gene-Targeting Strategy Identifies Synthetic Lethal Interactions between MK2 and p53 in the DNA Damage Response In Vivo
Morandell, S., Reinhardt, H. C., Cannell, I. G., Kim, J. S., Ruf, D. M., Mitra, T., Couvillon, A. D., Jacks, T., & Yaffe, M. B. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.10.025 · Cited by 98
A Randomized Phase 3 Trial Comparing Pemetrexed/Carboplatin and Docetaxel/Carboplatin as First-Line Treatment for Advanced, Nonsquamous Non-small Cell Lung Cancer
Pereira, J. R., Kim, J.-H., Magallanes, M., Lee, K. H., Wang, J., Ganju, V., Martínez-Barrera, L. M., Barraclough, H., Kooten, M. V., & Orlando, M. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318226b5fa · Cited by 93

Authors: Azzoli, C. G., Baker, S., Temin, S., Pao, W., Aliff, T., Brahmer, J., Johnson, D. H., Laskin, J. L., Masters, G., Milton, D., Nordquist, L., Pfister, D. G., Piantadosi, S., Schiller, J. H., Smith, R., Smith, T. J., Strawn, J. R., Trent, D., & Giaccone, G.
Affiliations: American Society of Clinical Oncology (US)
ORCID: Azzoli, Christopher G.
Temin, Sarah
Pao, William
Brahmer, Julie
Johnson, David H.
Masters, Gregory
Pfister, David G.
Piantadosi, Steven
Schiller, Joan H.
Smith, Thomas J.
Giaccone, Giuseppe
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2009-12-20
Volume: 27
Issue: 36
Pages: 6251-6266
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2009.23.5622
PMC: PMC2793036
OpenAlex: W2119366998
Cited by: 915
References: 218
Citations by year: 2026: 6 · 2025: 4 · 2024: 9 · 2023: 8 · 2022: 12 · 2021: 25 · 2020: 21 · 2019: 33 · 2018: 38 · 2017: 38 · 2016: 67 · 2015: 89 · 2014: 111 · 2013: 128 · 2012: 119
FWCI: 90.05
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: stage IV non-small cell lung cancer, chemotherapy, first-line therapy, second-line therapy, third-line therapy, gefitinib, erlotinib, bevacizumab, carboplatin-paclitaxel, cetuximab, docetaxel, EGFR mutation, platinum-based doublets, overall survival, progression-free survival, treatment toxicity
MeSH terms: Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Neoplasm Staging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks